Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · Real-Time Price · USD
4.320
+0.070 (1.65%)
At close: Jul 30, 2026, 4:00 PM EDT
4.330
+0.010 (0.23%)
After-hours: Jul 30, 2026, 7:48 PM EDT

Aligos Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
4.712.193.9515.5313.914.36
Revenue Growth
45.76%-44.59%-74.60%11.66%219.04%-
Gross Profit
4.712.193.9515.5313.914.36
Operating Income
-95.67-87.99-89.15-88.13-97.58-128.32
Net Income
-90.32-24.19-131.21-87.68-96.05-128.33
Earnings Per Share
-8.69-2.45-20.94-34.20-56.25-80.50
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
54.9177.8456.94135.7125.83190.73
Total Debt
4.355.258.3811.1412.5714.46
Net Cash (Debt)
50.5672.5948.56124.57113.25176.28
Net Cash Growth
-61.11%49.48%-61.01%9.99%-35.75%-23.52%
Net Cash Per Share
4.877.347.7548.5966.31110.57

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-84.72-82.5-80.74-79-79.39-115.66
Capital Expenditures
-0.46-0.44-0.13-0.02-0.94-0.89
Free Cash Flow
-85.19-82.94-80.87-79.02-80.33-116.55
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-2033.39%-4024.93%-2259.92%-567.50%-701.66%-2943.82%
Pretax Margin
-1907.18%-1092.36%-3317.62%-559.50%-689.87%-2940.79%
Profit Margin
-1919.68%-1106.72%-3326.01%-564.62%-690.63%-2944.07%
FCF Margin
-1810.52%-3794.14%-2050.01%-508.83%-577.64%-2673.87%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
5.6826.2436.233.202.93116.05